Farsight Medical Announces First Patient Dosed in Phase II Clinical Trial of RN-0001, a World-First Therapy for Acute Pancreatitis
January 31, 2026
Source: https://bydrug.pharmcube.com/news/detail/d9c3d25d741a604efb7e07c485b06c94
36
Farsight Medical Technology (Shanghai) Co., Ltd. (hereinafter referred to as "Farsight Medical") is dedicated to the field of cyclophilin inhibitors. Leveraging its proprietary technology platform, the company focuses on mechanistic research and drug development centered around cyclophilin A (CypA)-related inflammatory pathways and cyclophilin D (CypD)/mitochondrial permeability transition pore (mPTP)-related mitochondrial damage.
The company recently announced that its global first-in-class innovative drug, RN-0001, for the treatment of acute pancreatitis (AP) complicated by systemic inflammatory response syndrome (SIRS), successfully completed the first patient enrollment and dosing in its Phase II multicenter clinical trial on January 28, 2026, at the lead site, West China Hospital of Sichuan University.
Currently, RN-0001 has been approved by the NMPA to conduct Phase II clinical trials. This newly initiated multicenter study aims to systematically evaluate the efficacy, safety, and pharmacokinetic (PK) profiles of the drug in patients with acute pancreatitis.
By editor
Copyright©2026 Ddu. All rights reserved.
Read more on
- Strategic Collaboration with AstraZeneca, Potential Transaction Value Up to $18.5 Billion January 31, 2026
- Boao Lecheng CGT project reaches 20 items! The first autologous NK therapy for eight types of cancer in China has been approved, costing 49,800 yuan per treatment January 31, 2026
- Yangtze River Pharmaceutical Group is ramping up its investment in the 10 billion yuan contrast agent market, aiming to challenge Hengrui January 31, 2026
- Simcere Pharmaceutical’s TL1A/IL-23p19 bispecific antibody goes global, partnering with Boehringer Ingelheim to expand the global inflammatory bowel disease market. January 31, 2026
- Within 29 days of its listing, Insilicon has secured four collaborations. January 31, 2026
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
